Caissa Capital Management ltd. - 18 May 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
18 May 2023
Net transactions value
+$89,372
Form type
4
Filing time
22 May 2023, 16:30:01 UTC
Previous filing
16 May 2023
Next filing
24 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common stock Purchase $43,163 +13,121 +0.97% $3.29* 1,360,200 18 May 2023 See Footnote (1) F1, F2
transaction AVTX Common stock Purchase $22,852 +6,500 +0.48% $3.52* 1,366,700 19 May 2023 See Footnote (1) F1, F3
transaction AVTX Common stock Purchase $23,358 +7,000 +0.51% $3.34* 1,373,700 22 May 2023 See Footnote (1) F1, F4
holding AVTX Common stock 182,300 18 May 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.40, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4 to $3.6, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.72, inclusive.
F5 These share are directly owned by Mr. Golestaneh in his personal capacity.